2022-06-14

Realheart’s CEO in Filmed Company Presentation: “the biggest news for 2022 is that the clinical version of Realheart® TAH is fully developed and under production”

In a filmed presentation on the occasion of Realheart's Annual General Meeting, CEO Ina Laura Perkins describes what the company has done during the past year and what is in the pipeline for 2022.

Among other things, Ina Laura explains what the four key factors for success are and why the Company has started a subsidiary in Australia.

Link to the Filmed Presentation: https://youtu.be/DQAErlgdRBE

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.

Realheart's CEO in Filmed Company Presentation: "the biggest news for 2022 is that the clinical version of Realheart® TAH is fully developed and under production"